Physician profile
Amit R Mehta
NPI 1740460377
$4,309,585.02
in general payments reported to CMS, 2019-2025
50 companies · $808K in 2025
The $808K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563K · 2020: $349K · 2021: $523K · 2022: $726K · 2023: $705K · 2024: $636K · 2025: $808K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.4M · Travel and Lodging: $391K · Consulting Fee: $226K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $69K · Honoraria: $53K · Food and Beverage: $39K · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,370,663.89 |
| Travel and Lodging | $391,191.35 |
| Consulting Fee | $226,110.27 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $68,670.50 |
| Honoraria | $53,163.69 |
| Food and Beverage | $38,734.05 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $558,743.43 | 2019-2025 | |
| Incyte Corporation | $529,816.96 | 2020-2025 | Monjuvi, Monjuvi, Jakafi |
| Emd Serono, INC. | $512,263.81 | 2019-2025 | Bavencio |
| Astellas Pharma US INC | $472,196.67 | 2019-2025 | Xtandi, Padcev |
| Rigel Pharmaceuticals, INC. | $371,936.30 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmaessentia USA Corporation | $314,478.48 | 2022-2025 | Besremi |
| Janssen Biotech, INC. | $282,506.00 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Merck Sharp & Dohme LLC | $201,966.63 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $194,209.39 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $194,174.96 | 2021-2025 | Fotivda |
| Amag Pharmaceuticals, INC. | $159,767.11 | 2019-2021 | |
| Pharming Healthcare, INC. | $105,356.26 | 2022-2025 | Joenja, Ruconest |
| E.R. Squibb & Sons, L.L.C. | $83,433.67 | 2019-2024 | Eliquis, Camzyos |
| Geron Corporation | $68,059.63 | 2024-2025 | Rytelo, Imetelstat |
| Pharmacosmos Therapeutics INC. | $63,427.57 | 2021-2024 | Monoferric |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $49,435.31 | 2021-2023 | |
| Recordati_rare_diseases_inc. | $41,033.85 | 2024-2025 | Sylvant |
| Ipsen Biopharmaceuticals, INC | $32,411.89 | 2023-2024 | Tazverik, Iqirvo |
| Novartis Pharmaceuticals Corporation | $17,537.31 | 2019-2025 | |
| Eusa Pharma (US) LLC | $13,971.63 | 2020-2022 | |
| Seagen INC. | $11,747.48 | 2019-2023 | Padcev, Tukysa |
| Gilead Sciences, INC. | $8,130.69 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $7,798.42 | 2024 | Orgovyx |
| Syndax Pharmaceuticals, INC. | $5,546.11 | 2025 | Revuforj |
| Morphosys, US INC. | $3,091.14 | 2021-2022 | |
| Medtronic, INC. | $1,865.57 | 2025 | Pipeline, Mo.Ma Ultra, Abre |
| Celgene Corporation | $1,798.35 | 2019-2023 | Reblozyl |
| Epizyme, INC. | $984.82 | 2021-2023 | Tazverik |
| Medical Device Business Services, INC. | $457.52 | 2024 | Cerepak Uniform, Emboguard, Trufill |
| Adaptive Biotechnologies Corporation | $321.72 | 2021-2025 | Clonoseq |
| Exelixis INC. | $314.25 | 2019-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $117.82 | 2019-2024 | Hyqvia |
| Janssen Scientific Affairs, LLC | $92.74 | 2025 | Akeega, Erleada |
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 | |
| Glaxosmithkline, LLC. | $54.91 | 2021-2024 | Jemperli, Zejula |
| Dova Pharmaceuticals | $52.66 | 2019 | |
| Daiichi Sankyo INC. | $52.47 | 2019-2022 | |
| Cti Biopharma Corp. | $49.72 | 2023 | Vonjo |
| Amgen INC. | $40.77 | 2019-2024 | Lumakras |
| Astrazeneca Pharmaceuticals Lp | $34.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.54 | 2019-2021 | |
| Kyowa Kirin, INC. | $30.05 | 2019 | |
| Eisai INC. | $29.08 | 2021-2023 | |
| Olympus America INC. | $25.50 | 2019-2020 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.28 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $15.82 | 2019 | |
| Deciphera Pharmaceuticals INC. | $14.28 | 2020 | |
| Apellis Pharmaceuticals, INC. | $13.92 | 2024 | Empaveli |
| Genentech USA, INC. | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.